IL157301A0 - Preparations and use of an ah receptor ligand, 2-(1'h-indole-3'-carbonyl)-thiazole-4-carboxylic acid methyl ester - Google Patents

Preparations and use of an ah receptor ligand, 2-(1'h-indole-3'-carbonyl)-thiazole-4-carboxylic acid methyl ester

Info

Publication number
IL157301A0
IL157301A0 IL15730102A IL15730102A IL157301A0 IL 157301 A0 IL157301 A0 IL 157301A0 IL 15730102 A IL15730102 A IL 15730102A IL 15730102 A IL15730102 A IL 15730102A IL 157301 A0 IL157301 A0 IL 157301A0
Authority
IL
Israel
Prior art keywords
thiazole
indole
carbonyl
preparations
carboxylic acid
Prior art date
Application number
IL15730102A
Other languages
English (en)
Original Assignee
Wisconsin Alumni Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wisconsin Alumni Res Found filed Critical Wisconsin Alumni Res Found
Publication of IL157301A0 publication Critical patent/IL157301A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL15730102A 2001-02-14 2002-02-12 Preparations and use of an ah receptor ligand, 2-(1'h-indole-3'-carbonyl)-thiazole-4-carboxylic acid methyl ester IL157301A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26880901P 2001-02-14 2001-02-14
PCT/US2002/004137 WO2002064138A1 (en) 2001-02-14 2002-02-12 Preparations and use of an ah receptor ligand, 2-(1'h-indole-3'-carbonyl)-thiazole-4-carboxylic acid methyl ester

Publications (1)

Publication Number Publication Date
IL157301A0 true IL157301A0 (en) 2004-02-19

Family

ID=23024571

Family Applications (2)

Application Number Title Priority Date Filing Date
IL15730102A IL157301A0 (en) 2001-02-14 2002-02-12 Preparations and use of an ah receptor ligand, 2-(1'h-indole-3'-carbonyl)-thiazole-4-carboxylic acid methyl ester
IL157301A IL157301A (en) 2001-02-14 2003-08-07 Preparations and use of ligand bound to the AH receptor which is - H) 2 '1 indole – 3' – carbonyl) thiazole – 4 – carboxylic acid methyl ester

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL157301A IL157301A (en) 2001-02-14 2003-08-07 Preparations and use of ligand bound to the AH receptor which is - H) 2 '1 indole – 3' – carbonyl) thiazole – 4 – carboxylic acid methyl ester

Country Status (13)

Country Link
US (1) US6916834B2 (de)
EP (1) EP1365760B1 (de)
JP (1) JP4509478B2 (de)
AT (1) ATE431823T1 (de)
AU (1) AU2002248422B2 (de)
BR (1) BR0207689A (de)
CA (1) CA2437579C (de)
DE (1) DE60232403D1 (de)
ES (1) ES2327615T3 (de)
IL (2) IL157301A0 (de)
MX (1) MXPA03007245A (de)
NZ (1) NZ527430A (de)
WO (1) WO2002064138A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1642910A (zh) * 2002-02-12 2005-07-20 威斯康星校友研究基金会 用于ah受体作为配体的吲哚噻唑化合物的合成
JP2007516155A (ja) * 2003-10-14 2007-06-21 カウンシル オブ サイエンティフィク アンド インダストリアル リサーチ エストロゲン活性を有する（３ｒ，４ｒ）−トランス−３，４−ジアリールクロマン誘導体
EP1842541A1 (de) * 2006-03-29 2007-10-10 G.I.M.-Gesellschaft Für Innovative Medizin Gmbh Nfg Ohg Pflanzenextrakte, pflanzliche Wirkstoffe und ihre Verwendung
EP2082736A1 (de) 2008-01-23 2009-07-29 Jean Hilaire Saurat Pharmazeutische Zusammensetzung zur lokalen Anwendung
ES2791684T3 (es) * 2009-11-02 2020-11-05 Ariagen Inc ITE para la intervención y erradicación del cáncer
US10632106B2 (en) 2009-11-02 2020-04-28 Ariagen, Inc. Methods of cancer treatment with 2-(1′H-Indole-3′-carbonyl)-thiazole-4-carboxylic acid methyl ester
CN102775399A (zh) * 2011-12-27 2012-11-14 盛世泰科生物医药技术(苏州)有限公司 arylhydrocarbon受体(AHR)的内源性配体,2-(1’H3’-吲哚羰基)噻唑-4-羧酸甲酯的合成新方法
KR102282187B1 (ko) 2014-09-12 2021-07-26 아리아젠, 인크. 2-(1'h-인돌-3'-카르보닐)-티아졸-4-카르복실산 메틸 에스테르 및 그의 구조 유사체의 효율적이고 확장 가능한 합성
CN113480530A (zh) * 2016-12-26 2021-10-08 阿里根公司 芳香烃受体调节剂
WO2019099977A2 (en) * 2017-11-20 2019-05-23 Ariagen, Inc. Indole compounds and their use
US20210347794A1 (en) 2018-09-21 2021-11-11 Ariagen, Inc. Phosphate Derivatives of Indole Compounds and Their Use
TW202038943A (zh) * 2018-11-19 2020-11-01 美商雅里俊公司 治療癌症之方法
TW202104218A (zh) 2019-04-15 2021-02-01 美商雅里俊公司 對掌性吲哚化合物及其用途
US11136318B2 (en) 2019-06-21 2021-10-05 Noramco, Llc Processes for the preparation of aryl hydrocarbon receptor ligands

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3285931A (en) * 1964-12-21 1966-11-15 Union Carbide Corp Preparation of substituted pyrrole derivatives
GB9215361D0 (en) * 1992-07-20 1992-09-02 Wellcome Found Heterocyclic compounds
US5336685A (en) * 1993-04-12 1994-08-09 Sloan-Kettering Institute For Cancer Research Use of flavonoids to treat multidrug resistant cancer cells
US6323228B1 (en) * 2000-09-15 2001-11-27 Abbott Laboratories 3-substituted indole angiogenesis inhibitors
CN1642910A (zh) * 2002-02-12 2005-07-20 威斯康星校友研究基金会 用于ah受体作为配体的吲哚噻唑化合物的合成

Also Published As

Publication number Publication date
NZ527430A (en) 2005-03-24
IL157301A (en) 2012-03-29
JP2004527482A (ja) 2004-09-09
JP4509478B2 (ja) 2010-07-21
US20020183524A1 (en) 2002-12-05
AU2002248422B2 (en) 2006-07-06
WO2002064138A1 (en) 2002-08-22
MXPA03007245A (es) 2004-06-30
EP1365760B1 (de) 2009-05-20
EP1365760A1 (de) 2003-12-03
BR0207689A (pt) 2004-03-09
DE60232403D1 (de) 2009-07-02
CA2437579C (en) 2012-05-01
ES2327615T3 (es) 2009-11-02
ATE431823T1 (de) 2009-06-15
EP1365760A4 (de) 2004-07-14
CA2437579A1 (en) 2002-08-22
US6916834B2 (en) 2005-07-12

Similar Documents

Publication Publication Date Title
UY26082A1 (es) Derivados de 1,4-diazabiciclo [3.2.2] nonan-4-carboxilato y -carboxamidas, su preparacion y su aplicacion en terapeutica
AU4300701A (en) Methods and compositions for administration of therapeutic reagents
ATE431823T1 (de) Zubereitungen und verwendung eines ah-rezeptor- liganden, 2-(1'h-indol-3'-carbonyl)-thiazol-4- carbonsäure-methylester
AU2001263229A1 (en) Compositions and methods for administration of pharmacologically active compounds
FR16C1012I2 (fr) Utilisation therapeutique d'anticorps anti-cs1
DE60235719D1 (de) Frauenhygieneartikel zur verabreichung von arzneimittel
ZA96683B (en) New stabilized galenic formulations comprising an acid labile benzimidazole compound and its preparation
EP1171117A4 (de) Langzeitverabreichung von pharmakologisch aktiven mitteln
AU3730600A (en) Compositions preparations and uses of human papillomavirus l1 protein
NO20006055D0 (no) Fremstilling av hydrolysat-smakspreparater
PL328998A1 (en) Combined preparation containing (4-trifluoromethyl) 5-methylisoxazole-4-carboxylic anilide and n-(4-trifluoromethylphenyl)-2-cyano-3-hydroxycortonamide
AU5428700A (en) Acrylic acid derivatives, use of the same and intermediates for the preparation thereof
ITMI20010733A0 (it) Uso di inibitori dell'isoenzina cox-2 per il trattamento dell'incontinenza urinaria
WO2003020200A3 (en) A novel pharmaceutical compound and methods of making and using same
HUP0201038A2 (en) Preparations for the application of anti-inflammatory agents
EP1370241A4 (de) Multilamellare emulsion (mle) zur stabilisierung dermatologisch nützlicher inhaltsstoffe und externer basenzubereitungen für allgemeine hauterkrankungen
AU3471400A (en) Compositions and methods for controlled delivery of virus vectors
AU5026600A (en) Methods of regulating the condition of mammalian keratinous tissue
AU6901000A (en) Bioartificial device for propagation of tissue, preparation and uses thereof
AU2001265280A1 (en) Preparation of 2-hydroxy-5-oxoproline and analogs thereof
AU1790497A (en) Preparation of methyl 2-(2-methylphenyl)-3-methoxyacrylate
AU2002322424A1 (en) Novel methods and formulations for administration of active agents
TR199900013T2 (xx) Yeni bile�ikler.
TR200202110T2 (tr) "5-[{6-(2-Flüore benzil) oksi-2-naftil}metil]-2,4-tiyazolidin dion kristalleri"
AU2001271281A1 (en) Novel compositions for the expression of the human peptide histidine transporter1 and methods of use thereof